Sponsored By
An organization or individual has paid for the creation of this work but did not approve or review it.



Avera will take part in study of plasma therapy for COVID-19 cases

A view of the Avera McKennan Hospital and University Health Center campus from an Avera helicopter as part of their Careflight service. (Matt Gade / Republic)
A view of the Avera McKennon Hospital and University Health Center campus from an Avera helicopter as part of their Careflight service. Careflight helicopters will serve a 125 mile radius from their two locations, the one at McKennan and the other based in Aberdeen. (Matt Gade / Republic)

Avera Health said this week it has joined a national coalition to test the effectiveness of convalescent plasma as a therapy for COVID-19 patients.

The Food and Drug Administration announced April 3 that Mayo Clinic would lead a national initiative to expand access to convalescent plasma treatment. Avera is one of 1,046 participating sites.

Anyone who has had a positive test for COVID-19 and has now recovered from the illness is a potential plasma donor to help COVID-19 patients. They can call the Avera Center for Pediatric and Community Research at 605-504-3154 or email COVID19Plasma@avera.org to learn more about donating blood plasma.

Patients can only receive this treatment if they are hospitalized. The therapy involves the infusion of donated blood plasma from an individual who has recovered from COVID-19 into a patient who is hospitalized with severe or life-threatening symptoms of the virus.

“Patients who have recovered from COVID-19 have antibodies in their blood that could be beneficial to patients who are still fighting the most severe symptoms of this illness,” said Vinod Parameswaran, MD, Avera Medical Group hematologist. “Blood plasma therapy has been used from time to time over the last century, for example, during the 1918 influenza pandemic, and more recent SARS and Ebola outbreaks. We are excited to be part of this major health initiative.”


Small studies internationally have shown improvement of symptoms, leading to this wider scale expanded access program. To participate, patients must meet certain criteria, including being at least 18 years old who are hospitalized with a positive COVID-19 diagnosis and experiencing severe or life-threatening symptoms. Patients who receive the therapy will give their consent or have consent given by their legally authorized representative if they are incapacitated.

“We recognized the importance of this study and we recognized our wherewithal to bring everything together to join this initiative. Typically, participating in a research study like this would take months of preparation, but we got it accomplished within a short time. This took a very collaborative spirit that’s prevalent at Avera. This is a very promising therapeutic option in the treatment of COVID-19 hospitalized patients and we are thrilled to participate,” said Avera Medical Group infectious disease specialist Dr. Jawad Nazir.

What To Read Next
Get Local